ライフサイエンスコーパス: MEN 2B

コーパス検索結果 (left1)

通し番号をクリックするとPubMedの該当ページを表示します

1 MEN 2B patients, running a high risk of metastatic MTC,

2 The clinical subtypes of MEN 2 (MEN 2A, MEN 2B and familial MTC) all have medullary thyroid carc

3 Multiple endocrine neoplasia type 2B (MEN 2B) is caused by the mutation of a conserved methion

4 A) and multiple endocrine neoplasia type 2B (MEN 2B) syndromes.

5 sis of multiple endocrine neoplasia type 2B (MEN 2B).

6 In multiple endocrine neoplasia 2B (MEN-2B) patients expressing RET(M918T), nuclear enrichme

7 the 61 patients (59%) responded (MEN 2A = 8, MEN 2B = 28) to the questionnaires.

8 ocrine neoplasia types 2A and 2B (MEN 2A and MEN 2B) and familial medullary thyroid carcinoma (FMTC),

9 ction distinct from that known for classical MEN 2B mutations.

10 Forty-four MEN 2B patients carrying inherited (3 patients) and de n

11 ytoma (pheo), and hyperparathyroidism (HPT); MEN 2B, by MTC, pheo, and characteristic stigmata; and f

12 th the presence of skeletal abnormalities in MEN 2B patients.

13 , cutaneous lesions classically described in MEN 2B syndrome, and 1 relative also showing multiple sc

14 may explain the early onset of malignancy in MEN 2B compared with MEN 2A patients.

15 eletal abnormalities and early malignancy in MEN 2B compared with MEN 2A syndrome.

16 th factor beta pathway, were up-regulated in MEN 2B MTCs.

17 was expressed at high levels specifically in MEN 2B MTCs.

18 only with FMTC, while codon 918 mutation is MEN 2B--specific.

19 Among 41 patients with de novo mutations, MEN 2B was diagnosed in 12 patients after recognition of

20 nts with de novo mutations when nonendocrine MEN 2B components are quickly appreciated and surgical i

21 bute to understanding the molecular basis of MEN 2B, and will assist in the clinical management of fa

22 918T, has been identified in 94% of cases of MEN 2B (which consists of MTC, pheochromocytoma and deve

23 RET mutation (A883F) in two de novo cases of MEN 2B.

24 Comparisons of MEN 2B and MEN 2A MTCs revealed that genes involved in t

25 nts with de novo mutations, the diagnosis of MEN 2B was triggered by symptomatic MTC (28 patients) or

26 N 2B mutation does not cause any features of MEN 2B in mice.

27 rtained a patient with classical features of MEN 2B, but lacking either of the classical mutations in

28 re examined for signs and symptoms prompting MEN 2B.

29 ltiple endocrine neoplasia type 2B syndrome (MEN 2B).

30 These data demonstrate that the MEN 2B point mutation alters the substrate specificity o

31 When the MEN 2B point mutation was introduced into the epidermal

32 ssion of a human Ret proto-oncogene with the MEN 2B mutation does not cause any features of MEN 2B in

33 the enhanced oncogenesis associated with the MEN 2B mutation may be due in part to alterations in rec

34 This MEN 2B MTC profile may explain the early onset of malign

35 yndrome include macular amyloidosis, whereas MEN 2B syndrome is traditionally linked to multiple muco

36 ultiple endocrine neoplasia [MEN] 2A, 4 with MEN 2B, 1 each with von Hippel-Lindau and neurofibromato

37 ny of the expected neoplasms associated with MEN 2B.

38 One patient with MEN 2B underwent open adrenalectomy due to previous adre

39 These and all patients with MEN 2B followed at the authors' institution (n = 53) wer

40 Ninety-three percent of patients with MEN 2B had gastrointestinal symptoms 1 to 24 years befor

41 sprung's disease (HD), and all patients with MEN 2B have intestinal neuromas and megacolon that can c

42 Patients with MEN 2B have significant gastrointestinal symptoms, but l

43 Seventy-one percent of patients with MEN-2B with gastrointestinal symptoms had radiographic i

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。